New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
06:59 EDTVSTMVerastem data compelling, says Cantor
After Verastem reported data from its Phase Ib combination study of defactinib in combination with docetaxel for the treatment of ovarian cancer, Cantor remains upbeat about the company's overall pipeline. It keeps a $22 price target and Buy rating on the stock.
News For VSTM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 13, 2015
11:04 EDTVSTMVerastem receives orphan status for treatment of ovarian cancer
The granted Verastem orphan status for defactinib, its treatment of ovarian cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use